Appetite is expected to come back as the medicine leaves your body. Semaglutide 2.4 mg is present for about 5 to 7 weeks after the last dose, and tirzepatide's half-life is about 5 to 6 days (label, label). No trial has measured hunger after stopping. Through the GetLean GLP-1 Taper Plan, Dr Quek steps the dose down at monthly reviews instead, where clinically appropriate.
The three landmark withdrawal trials, the STEP 1 extension, STEP 4 and SURMOUNT-4, recorded body weight and cardiometabolic markers, not appetite, hunger, craving or food intake. Semaglutide's elimination half-life is about one week (label). Food noise, the preoccupation with food many people say quietens on treatment, has not been measured after stopping either: the first validated questionnaire for it appeared in 2025 (Diktas 2025), and what is food noise covers what is and is not known. At GetLean you don't stop overnight: Dr Quek plans your taper from the first consultation, where clinically appropriate, and steps the dose down at the monthly reviews.
In Singapore, tirzepatide is registered as Mounjaro, and semaglutide injection as Wegovy for weight management and as Ozempic for type 2 diabetes. The figures in this article are given by molecule, as the trials and product labels report them.
Withdrawal trial: a study in which people who lost weight on a medication stop taking it, either by switching to placebo or by ending treatment, so the effect of stopping can be measured. The three main ones here are the STEP 1 extension, STEP 4 and SURMOUNT-4.
What the withdrawal trials measured
Weight, and markers. That is the list.
The STEP 1 extension followed 327 participants for a year after semaglutide and the trial's lifestyle support were stopped overnight, with no taper, and reported that about two-thirds of the lost weight returned (Wilding 2022). STEP 4 and SURMOUNT-4 likewise reported weight outcomes.
None of the three reported an appetite, hunger, craving or energy-intake outcome after discontinuation.
Appetite measurement is intensive — laboratory test meals or validated questionnaires — and it was generally done during treatment rather than in the follow-up period after treatment ended.
So: if you read that "cravings come roaring back" and it is attributed to these trials, the attribution is wrong. They did not look.
What was measured, during treatment
The picture on-treatment is much better documented, and it is worth knowing because it frames the inference.
In a crossover trial, semaglutide reduced total food intake across a single laboratory test day by about 24% compared with placebo (Blundell 2017) — a laboratory measurement, not tracked daily eating. In the STEP 5 sub-study, craving-control scores on a self-report instrument improved significantly versus placebo at weeks 20, 52 and 104 (STEP 5 sub-study). Those are mean differences on a questionnaire, not the elimination of cravings.
So the medication demonstrably changes appetite and craving measures while it is being taken. What happens to those measures afterwards was not followed.
What has been measured about appetite and craving, and when.
| Measure | When | What was reported | Source |
|---|---|---|---|
| Total food intake across a single laboratory test day | During treatment, in a crossover trial | About 24% lower on semaglutide than on placebo; a laboratory measurement, not tracked daily eating | Blundell 2017 |
| Craving-control scores on a self-report instrument | During treatment, at weeks 20, 52 and 104 | Improved significantly versus placebo; mean differences on a questionnaire, not the elimination of cravings | STEP 5 sub-study |
| Appetite, hunger, craving or energy intake | After discontinuation | Not reported by the STEP 1 extension, STEP 4 or SURMOUNT-4, which recorded body weight and cardiometabolic markers | STEP 1 extension: Wilding 2022 |
What the pharmacology implies
Semaglutide has an elimination half-life of approximately one week, and the label states that it "will be present in the circulation for about 5 to 7 weeks after the last dose of 2.4 mg" (label). Tirzepatide's elimination half-life is approximately 5 to 6 days (label).
The medication therefore leaves the body over weeks rather than days. Since the appetite effect is produced by the drug acting on receptors, it is reasonable to expect that effect to diminish as the drug clears.
Two caveats matter. Half-life describes drug concentration, not the duration of downstream physiological effect — those can differ. And nobody has measured the time course of appetite return, so "over several weeks" is an inference from clearance rather than an observed finding.
The weight data fit that picture: in the STEP 1 extension, where the medication was stopped overnight with no taper, weight began moving back up once treatment ended (Wilding 2022). That is why we favour a gradual reduction under a doctor's guidance rather than a cliff-edge stop: at GetLean the dose is stepped down at Dr Quek's monthly reviews, which allows appetite to adjust incrementally.
Why the distinction is worth making
Because it changes what you plan for.
If appetite return were a documented, characterised process with a known timeline, you could plan around the timeline. It is not, so you cannot. What can be planned around is what the trials showed when the medication was taken away: when the STEP 1 extension stopped it overnight, the weight started coming back promptly. So the plan at GetLean avoids an overnight stop: the habits are built while appetite is still quiet, and the dose comes down gradually.
There is also a physiological headwind independent of the medication. After weight loss, reduced body weight is defended by a coordinated set of metabolic, neuroendocrine and behavioural responses opposing sustained weight loss (Rosenbaum 2010). That is biology, not a lack of willpower, and it is why the habits that meet it are built in the months before the dose comes down rather than in the weeks after.
We cover the regain data itself in why two-thirds of the weight comes back.
What to do with an unmeasured variable
Build the things that do not depend on appetite being suppressed.
An eating pattern that has become ordinary rather than effortful does not stop working when a prescription ends. A training habit that is already automatic does not require motivation to restart. And the lean mass you carry into that phase is the lean mass you kept — lean mass was statistically unchanged in the trials where resistance training accompanied caloric restriction (Lopez 2022).
Exercise alongside the medication also has a trial result after stopping. In a Copenhagen randomised trial that followed adults for a year after treatment ended, those who had combined a GLP-1 medication with supervised exercise were more likely than those who had taken the medication alone to still hold a loss of at least 10% of their starting weight (Jensen 2024). The medication was liraglutide, an earlier GLP-1 medicine, and the initial loss came from a low-calorie diet.
None of that is a substitute for the appetite effect. It is the set of things that still exist once the appetite effect is gone, and it takes months to establish, which is why it belongs at the start of treatment rather than at the end.
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. On this particular question that philosophy is doing something concrete: since nobody can tell you what your appetite will do, the sensible move is to build what does not depend on knowing.
Individual results vary, and clinical-trial figures describe the populations studied. Stopping or changing a prescribed medication is a decision to make with your doctor.
What happens after the taper at GetLean?
Finishing the taper does not have to end the support. After the taper, a patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time: a restart begins with a review consultation, and whether to restart the medication is his decision at that review.
Designed to end: a programme whose pace and taper off the medication are planned from the first consult, so the result holds after the medication stops.
Common questions
Does appetite come back after stopping GLP-1 medication?
The appetite effect is produced by the medication, so it is expected to fade as the drug clears over the following weeks; the withdrawal trials recorded body weight rather than appetite, so its exact time course has not been charted. That is why the eating pattern and training habit are built while the medication is still working, and why at GetLean the dose is stepped down at Dr Quek's monthly reviews rather than stopped overnight, so appetite can adjust incrementally.
How long does GLP-1 medication stay in your system?
Semaglutide's elimination half-life is about one week, and the label states it is present in the circulation for roughly 5 to 7 weeks after a last 2.4 mg dose (label). Tirzepatide's is about 5 to 6 days (label).
Will cravings return exactly as before?
Nobody has measured it, so anyone stating a specific pattern is going beyond the evidence. What is documented is that craving-control scores improved on treatment (STEP 5 sub-study), which is one reason the eating pattern is built while the medication is still working.
How quickly does appetite change after the last dose?
Not measured. Half-life tells you how long the drug is present, not how quickly the effect fades — those are different things (labels).
What can you actually do about it?
Build the eating pattern and training habit while appetite is still suppressed, and protect the lean mass you take into that phase — resistance training kept lean mass statistically unchanged in the trials that combined it with caloric restriction (Lopez 2022).
What happens after the taper at GetLean?
A patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time; a restart begins with a review consultation, and whether to restart the medication is his decision.